<DOC>
	<DOC>NCT01951235</DOC>
	<brief_summary>This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus placebo. The study will be performed in subjects with type 2 diabetes either naive of treatment or previously treated with an oral monotherapy excluding thiazolidinedione.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Subject has given written informed consent 2. Male and female type 2 diabetic subjects, either naïve of antidiabetic agents or treated with an oral antidiabetic monotherapy. 3. Body mass index (BMI) : ≥ 24 to ≤ 40 kg/m² 4. HbA1c criteria: ≥ 7% and ≤ 9.5% 5. Creatinine clearance ≥ 50 mL/[min*1.73 m2] at Screening Visit 6. Effective contraception for women of child bearing potential 1. Any disease which in the investigator's opinion would exclude the subject from the study 2. Acute cardiovascular event within 3 months before randomization 3. Uncontrolled high blood pressure 4. Impairment of hepatic function 5. History of druginduced Torsades de Pointes or a marked baseline prolongation of the QTc interval 6. Pregnancy or lactation 7. Use of any nonpermitted medication 8. Positive screen for viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>